Eliem Therapeutics

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.

PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investigation seeks to determine whether Eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating the securities laws and causing harm to the company's shareholders.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh encourages Eliem shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Eliem and its board violated the.

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Companies to host webcast today, April 11, 2024 at 8:30 a.m. EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after completing a review of the company and its various programs.

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle and Cambridge, U.K.-based company said it has halted the development of its Kv7 program, which was focused on treatments for pain and epilepsy.

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in the process.

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel  opener program

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem's president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023

Eliem Therapeutics Provides Update on Pipeline Progress

Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Shares of Eliem Therapeutics Inc. ELYM, -11.51% tumbled 20.0% in premarket trading on Tuesday after the company said it will discontinue development of its treatment for lumbosacral radicular pain after a Phase 2a clinical trial didn't yield strong enough results. Eliem said it has enough capital to fund the development of other therapies and its operations through mid-2024.

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued

Eliem Therapeutics Provides ETX-810 Program Update

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced it will host a virtual investor event on Thursday, July 21, 2022 starting at 10:30 a.m. ET.

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Revlon

Tuscan Holdings Corp II

TherapeuticsMD

Weber

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Beam Global

Insignia Systems

JOANN

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

Veru

Vertex Energy

Camping World Hlds

Medavail Holdings Inc

Short squeeze stocks are once again in focus this week as the bears continue to run wild in the stock market. The post Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc.  (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2022.

News for Eliem Therapeutics Stock (ELYM)